remogliflozin-etabonate and dapagliflozin

The present review summarizes the existing literature data regarding the development of newer categories of antidiabetic agents, their mechanism of action and their clinical importance. In this paper, a review of the recent patents for the treatment of diabetes will be presented. In recent years significant achievements have been done, including the development of SGLT2 inhibitors, glucokinase activators as well as the role of free fatty acids and bile acid metabolism in the treatment of diabetes are reviewed.

Topics: Animals; Benzhydryl Compounds; Bile Acids and Salts; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucokinase; Glucosides; Humans; Hypoglycemic Agents; Molecular Targeted Therapy; Patents as Topic; Pyrazoles; Sodium-Glucose Transporter 2 Inhibitors

Inhibition of the sodium-glucose co-transporters (SGLT1 and SGLT2) is a validated strategy to address the increasing prevalence of type II diabetes mellitus. However, achieving selective inhibition of human SGLT1 or SGLT2 remains challenging. Orally available small molecule drugs based on the d-glucose core of the natural product Gliflozin have proven to be clinically effective in this regard, effectively impeding glucose reabsorption. Herein, we disclose the influence of molecular editing with fluorine at the C2 position of the pyranose ring of Phlorizin analogues Remogliflozin Etabonate and Dapagliflozin (Farxiga

Topics: Administration, Oral; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Fluorine; Glucosides; Glycosylation; Humans; Hypoglycemic Agents; Pyrazoles; Sodium-Glucose Transporter 2 Inhibitors